London-based Basecamp Research has raised $140 million (€122 million) in an oversubscribed Series C to expand its biological AI models and move a preclinical therapeutics pipeline toward the clinic.

Roche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped ...

German biotech ViferaXS has closed a Series A financing of up to €12 million, including grant funding, to advance its peptide-based cancer immunotherapy into a randomized Phase 2 trial in chronic ...

UK biotech Scarlet Therapeutics will lead a consortium developing red blood cells that can sense physiological changes and respond to them under a U.S. Defense Advanced Research Projects Agency (DARPA ...